Sugi Predict

Sugi Predict / Targets / PARP3

PARP3

Protein mono-ADP-ribosyltransferase PARP3 · Q9Y6F1 · PARP3 on Sugi Atlas →

25,744 patent compounds predicted against PARP3, 18,243 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1422404 SCHEMBL1422404 1.00 12/20
SCHEMBL853575 SCHEMBL853575 0.86 12/20
SCHEMBL854579 SCHEMBL854579 0.86 12/20
Bromide Bromide (SCHEMBL854522) 0.84 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL854721) 0.84 12/20
SCHEMBL854595 SCHEMBL854595 0.83 12/20
SCHEMBL854109 SCHEMBL854109 0.81 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL854284) 0.81 12/20
SCHEMBL854817 SCHEMBL854817 0.78 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL853885) 0.77 12/20
SCHEMBL854607 SCHEMBL854607 0.76 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL855640) 0.74 12/20
SCHEMBL854829 SCHEMBL854829 0.73 12/20
SCHEMBL854229 SCHEMBL854229 0.68 12/20
SCHEMBL854625 SCHEMBL854625 0.63 12/20
SCHEMBL853419 SCHEMBL853419 0.62 12/20
SCHEMBL854022 SCHEMBL854022 0.61 12/20
SCHEMBL854643 SCHEMBL854643 0.60 12/20
SCHEMBL853210 SCHEMBL853210 0.58 12/20
SCHEMBL854194 SCHEMBL854194 0.58 12/20

Clinical trials — most relevant to PARP3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation PHASE4ACTIVE_NOT_RECRUITING
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients PHASE3COMPLETED
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations PHASE1/PHASE2COMPLETED
Olaparib In Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) PHASE2RECRUITING
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure PHASE2UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer PHASE1UNKNOWN
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer PHASE1COMPLETED
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems PHASE1WITHDRAWN
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE
Sirtuin1 in COVID19 Patients nanUNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PARP3 binder may also engage these)

ProteinNameSimilarity
Q3ULW8 — 0.998 Q3ULW8 →
E1BSI0 — 0.984 E1BSI0 →
PARP2 Poly [ADP-ribose] polymerase 2 0.981 landscape →
O88554 — 0.978 O88554 →
D3ZND0 — 0.974 D3ZND0 →
Q9UJY4 — 0.972 Q9UJY4 →
Q9NVU0 — 0.972 Q9NVU0 →
P97452 — 0.971 P97452 →
Q9UNS1 — 0.970 Q9UNS1 →
Q99LG4 — 0.970 Q99LG4 →
Q5U2Q4 — 0.970 Q5U2Q4 →
Q9Z2Y1 — 0.970 Q9Z2Y1 →
Q8BMI3 — 0.970 Q8BMI3 →
Q7Z3D6 — 0.969 Q7Z3D6 →
Q4KLN4 — 0.969 Q4KLN4 →
Q9D479 — 0.969 Q9D479 →
Q9R1X4 — 0.969 Q9R1X4 →
Q91WR3 — 0.969 Q91WR3 →
RNF31 E3 ubiquitin-protein ligase RNF31 0.969 landscape →
O70576 — 0.969 O70576 →
Q924T7 — 0.968 Q924T7 →
Q8N0Z6 — 0.968 Q8N0Z6 →
Q9NWS0 — 0.968 Q9NWS0 →
F1ND48 — 0.968 F1ND48 →
Q6DDZ9 — 0.968 Q6DDZ9 →
Q562C2 — 0.968 Q562C2 →
P47823 — 0.968 P47823 →
IDO2 Indoleamine 2,3-dioxygenase 2 0.967 landscape →
Q9UJY5 — 0.967 Q9UJY5 →
Q99PL6 — 0.967 Q99PL6 →